FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy

SPOTLIGHT: Glaxo appraises Sirtris' potential


A somewhat skeptical Matthew Herper at Forbes did a Q&A with Glaxo's Patrick Vallance on the big news that it's buying Sirtris at $22.50 a share. Sirtris has been gaining headlines for its work in the anti-aging field, but the stock price has lagged significantly. Vallance sees great science, great scientists and lots of potential. One excerpt: "We're forever investing in high-risk things. That's what we do in the pharmaceutical industry. We're pretty clear that we see a big opportunity here." On big vs. small: "Now they can do things with a scale and know-how that's much more difficult if you're in a group of 60 people than if you're in a large organization that has done this for years." Report

More stories about GlaxoSmithKline   pharmaceutical industry  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 8 + 3?
To combat spam, please solve the math question above.